IL17A and colorectal carcinoma: Following disease progression, we further found that IL-1β, IL-17A and IL-23 were significantly higher in early stages than in advanced stages of CRA patients (IL-1β: 11.4 ± 0.6 pg/ml vs 6.2 ± 0.4 pg/ml, P < 0.001; IL-17A : 7.6 ± 1.2 pg/ml vs 4.7 ± 0.5 pg/ml, P = 0.038; IL-23: 42.8 ± 6.5 pg/ml vs 22.2 ± 3.1 pg/ml, P = 0.015) and CRC patients (9.3 ± 1.2 pg/ml vs 6.0 ± 0.5 pg/ml, P = 0.022; 25.1 ± 3.7 pg/ml vs 10.2 ± 2.8 pg/ml, P = 0.002; 68.4 ± 9.5 pg/ml vs 46.5 ± 6.2 pg/ml, P = 0.043).